Angela Reis-Rego

Dr. Angela Reis-Rego

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2019 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MSMariline Santos
Mariline Santos
ARAngela Reis-Rego
Angela Reis-Rego
MCMiguel Coutinho
Miguel Coutinho
CSCecília Almeida e Sousa
Cecília Almeida e Sousa
MFMiguel Ferreira
Miguel Ferreira

1 October 2023 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
MMMaria João Malaquias
Maria João Malaquias
LBLuis Braz
Luis Braz
CSCláudia Santos Silva
Cláudia Santos Silva
JDJoana Damásio
Joana Damásio
AJAndré Jorge
André Jorge
FGfor RFC1 Repeat Expansion National Study Group
for RFC1 Repeat Expansion National Study Group
Background and Objectives The RFC1 spectrum has become considerably expanded as multisystemic features beyond the triad of cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) have started to be unveiled, although many still require clinical replication. Here, we aimed to clinically characterize a cohort of RFC1-positive patients by addressing both classic and multisystemic features. In a second part of this study, we prospectively assessed small nerve fibers (SNF) and autonomic function in a subset of these RFC1-related patients. Methods We retrospectively enrolled 67 RFC1-positive patients from multiple neurologic centers in Portugal. All patients underwent full neurologic and vestibular evaluation, as well as neuroimaging and neurophysiologic studies. For SNF and autonomic testing (n = 15), we performed skin biopsies, quantitative sensory testing, sudoscan, sympathetic skin response, heart rate deep breathing, and tilt test. Results Multisystemic features beyond CANVAS were present in 82% of the patients, mainly chronic cough (66%) and dysautonomia (43%). Other features included motor neuron (MN) affection and motor neuropathy (18%), hyperkinetic movement disorders (16%), sleep apnea (6%), REM and non-REM sleep disorders (5%), and cranial neuropathy (5%). Ten patients reported an inverse association between cough and ataxia severity. A very severe epidermal denervation was found in skin biopsies of all patients. Autonomic dysfunction comprised cardiovascular (67%), cardiovagal (54%), and/or sudomotor (50%) systems. Discussion The presence of MN involvement, motor neuropathy, small fiber neuropathy, or extrapyramidal signs should not preclude RFC1 testing in cases of sensory neuronopathy. Indeed, the RFC1 spectrum can overlap not only with multiple system atrophy but also with hereditary motor and sensory neuropathy, hereditary sensory and autonomic neuropathy, and feeding dystonia phenotypes. Some clinical-paraclinical dissociations can pose diagnostic challenges, namely large and small fiber neuropathy and sudomotor dysfunction which are usually subclinical.

20 January 2018 in BMC Dermatology
Verified
Journal Article
Open access
PDF file
ZAZoe Argyropoulou
Zoe Argyropoulou
LLLu Liu
Lu Liu
LOLinda Ozoemena
Linda Ozoemena
CBClaudia Castelo Branco
Claudia Castelo Branco
RSRaquel Senra
Raquel Senra
LMLuisa Mota-Vieira
Luisa Mota-Vieira
Epidermolysis bullosa simplex with muscular dystrophy (EBS-MD; OMIM #226670) is an autosomal recessive disease, characterized mainly by skin blistering at birth or shortly thereafter, progressive muscle weakness, and rarely by alopecia. EBS-MD is caused by mutations in the PLEC gene (OMIM *601282), which encodes plectin, a structural protein expressed in several tissues, including epithelia and muscle. We describe a patient affected with EBS-MD and diffuse alopecia in which we identified a novel pathogenic mutation by PCR amplification of all coding exons and exon–intron boundaries of PLEC gene, followed by bidirectional Sanger sequencing. The patient, a 28-year-old female and only child of consanguineous healthy parents, was born after uneventful pregnancy. At 2 days of age, she developed skin and oral mucosal blistering, accompanied by voice hoarseness. On physical examination as an adult, we observed diffuse non-scarring alopecia on the scalp, onychodystrophy (pachyonychia) in all 20 nails, dental decay, mild dysphonia, and severe muscle atrophy mainly affecting the extremities. Neurological examination showed profoundly diminished reflexes. Mutation analysis revealed the patient to be homozygous for the novel PLEC nonsense mutation − c.7159G > T (p.Glu2387*) − located in exon 31. Thismutation predicts the lack of expression of the full-length plectin isoform. The present case appears to be the second association of EBS-MD with diffuse alopecia, both cases having different mutations involving PLEC exon 31. It remains to be elucidated whether diffuse alopecia results from PLEC mutations and/or from environmental factors.

1 June 2019 in Journal of Otology
Verified
Journal Article
Open access
ARAngela Reis-Rego
Angela Reis-Rego
DDDavid Dias
David Dias
APAna Pinto
Ana Pinto
SCSandra Sousa e Castro
Sandra Sousa e Castro
TFTelma Feliciano
Telma Feliciano
CSCecília Almeida e Sousa
Cecília Almeida e Sousa
MD is considered a rare disease. An adequate model that explains MD's pathophysiology is not well established. Recently, the vascular theory of the disease has been revived. To characterize a MD population according to its cardiovascular risk and correlate it to the MD clinical course. In this retrospective chart study the data of 31 MD patients observed between January 2017 and April 2018 in a tertiary university hospital were reviewed. Patients included in the study were diagnosed according to the Bárány Society criteria. Lost follow-ups, patients with autoimmune disease, atopy or allergy, major psychiatric disease and migraine were excluded. Age, gender, cardiovascular risk factors, audiometric and vestibular parameters, occurrence of MD attacks in the previous 6 months, vestibular medication in course and time course of MD were recorded and compared between groups (with and without cardiovascular risk factors). 31 patients (61.3% females) mean aged 60.3 years (±9.7) were studied. 74% of the population had at least one risk factor and 51.6% of patients had attacks in the last 6 months. There was a statistically significant difference in the occurrence of MD attacks in the last 6 months (p = 0.014) between MD patients with and without risk factors. Mean PTA thresholds were higher and speech discrimination was lower in individuals with more cardiovascular risk factors. Treatment of MD focusing on vascular risk factors may allow a better control of symptoms and result in a decreased need for ablative procedures in this disorder.

12 April 2016 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
ARAngela Reis-Rego
Angela Reis-Rego
Sofia VianaSofia Viana
Sofia Viana
CRCarlos Fontes Ribeiro
Carlos Fontes Ribeiro
Paulo Rodrigues-SantosPaulo Rodrigues-Santos
Paulo Rodrigues-Santos
FPFrederico Pereira
Frederico Pereira
Neuroinflammation is a two-edged sword in Alzheimer’s disease (AD). A certain degree of neuroinflammation is instrumental in the clearance of amyloid-β (Aβ) peptides by activated microglia, although a sustained neuroinflammation might accelerate Aβ deposition, thus fostering the neurodegenerative process and functional decline in AD. There is an increasing body of evidence suggesting that the innate immune system via Toll-like receptor 4 (TLR4) finely orchestrates the highly regulated inflammatory cascade that takes place in AD pathology. Herein we critically review pre-clinical ( in vitro and in vivo approaches) and clinical studies showing that monophosphoryl lipid A (MPL), a partial TLR4 agonist, may have beneficial effect on AD physiopathology. The in vivo data elegantly showed that MPL enhanced Aβ plaque phagocytosis thus decreasing the number and the size of Aβ deposits and soluble Aβ in brain from APPswe/PS1 mice. Furthermore, MPL also improved their cognition. The mechanism underlying this MPL effect was proposed to be microglial activation by recruiting TLR4. Additionally, it was demonstrated that MPL increased the Aβ antibody titer and showed a safe profile in mice and primates, when used as a vaccine adjuvant. Clinical studies using MPL as an adjuvant in Aβ immunotherapy are currently ongoing. Overall, we argue that the TLR4 partial agonist MPL is a potentially safe and effective new pharmacological tool in AD.

1 July 2019 in Journal of Voice
Verified
Journal Article
Closed access
ARAngela Reis-Rego
Angela Reis-Rego
PSPedro Henriques Santos
Pedro Henriques Santos
GSGustavo Santos
Gustavo Santos
DDDavid Dias
David Dias
SVSusana Vaz-Freitas
Susana Vaz-Freitas
CACecília Almeida
Cecília Almeida